Changes to the current vial stopper and potentially to the product delivery configuration are being evaluated following approximately 50 reports "from patients who are experiencing difficulties in penetrating the vial stopper with the needle on the supplied syringe, resulting in bent and otherwise damaged needles," firm says in recent "Dear Doctor" letter. The letter includes a revised video of instructions for preparing and administering Enbrel. The company said the letter was sent to prepare health care professionals in anticipation of Enbrel approval for the new indication of treatment of early stage rheumatoid arthritis (1"The Pink Sheet" April 24, p. 10). The user fee deadline for the sBLA is May 15
You may also be interested in...
Immunex will roll out a new series of direct-to-consumer print ads to support Enbrel for early rheumatoid arthritis following FDA approval of the new indication, expected this summer.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials